Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE scopes Sanofi/Regeneron's Zaltrap for colorectal cancer

This article was originally published in Scrip

Executive Summary

Sanofi/Regenron's Zaltrap (aflibercept) will shortly be up for review by NICE, the health technology appraisal institute for England and Wales, as a treatment for metastatic colorectal cancer that has progressed after oxaliplatin-based chemotherapy. The institute has put out for consultation its draft scope.

You may also be interested in...



New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

UK: Commercial Framework Sheds Light On Working With NHS And NICE

The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.

Time Is Ripe For Global Action On Orphan Biosimilars

European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel